{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:27Z","timestamp":1787315247612,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007470","name":"Shaqra University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.abb.2024.110066","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T12:06:24Z","timestamp":1718798784000},"page":"110066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Circulating tumor DNA (ctDNA) application in investigation of cancer: Bench to bedside"],"prefix":"10.1016","volume":"758","author":[{"given":"Hashem O.","family":"Alsaab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar A.","family":"Bahauddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar","family":"Almutairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abb.2024.110066_bib1","first-page":"241","article-title":"[Nuclear acids in human blood plasma]","volume":"142","author":"Mandel","year":"1948","journal-title":"Comptes Rendus Seances Soc. Biol. Ses Fil."},{"key":"10.1016\/j.abb.2024.110066_bib2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nm0996-1035","article-title":"Microsatellite alterations in serum DNA of head and neck cancer patients","volume":"2","author":"Nawroz","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.abb.2024.110066_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40246-019-0220-8","article-title":"Next-generation sequencing in liquid biopsy: cancer screening and early detection","volume":"13","author":"Chen","year":"2019","journal-title":"Hum. Genom."},{"key":"10.1016\/j.abb.2024.110066_bib4","first-page":"231","article-title":"Review ctDNA and Breast Cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer","volume":"215","author":"Clatot","year":"2020"},{"key":"10.1016\/j.abb.2024.110066_bib5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1515\/cclm-2021-0171","article-title":"Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?","volume":"59","author":"Duffy","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.abb.2024.110066_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ijc.33217","article-title":"Liquid biopsies: potential and challenges","volume":"148","author":"Heidrich","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","article-title":"Early detection of ovarian cancer","volume":"32","author":"Elias","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.abb.2024.110066_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113368","article-title":"Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer","volume":"195","author":"Helal","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib10","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.21.02615","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla","year":"2022","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.abb.2024.110066_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12943-022-01556-2","article-title":"Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer","volume":"21","author":"Zhou","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib12","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.abb.2024.110066_bib13","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.1994.tb04828.x","article-title":"Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia","volume":"86","author":"Vasioukhin","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.abb.2024.110066_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.abb.2024.110066_bib16","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.abb.2024.110066_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.abb.2024.110066_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107458","article-title":"Circulating tumor DNA as an early cancer detection tool","volume":"207","author":"Campos-Carrillo","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.abb.2024.110066_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2018.09.022","article-title":"Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions","volume":"14","author":"Chae","year":"2019","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib20","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.abb.2024.110066_bib21","doi-asserted-by":"crossref","first-page":"E1317","DOI":"10.1073\/pnas.1500076112","article-title":"Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients","volume":"112","author":"Jiang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.abb.2024.110066_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/0284186X.2022.2033831","article-title":"Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives","volume":"61","author":"Merk","year":"2022","journal-title":"Acta Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib23","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.abb.2024.110066_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-014-2946-2","article-title":"Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis","volume":"146","author":"Madhavan","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.abb.2024.110066_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12931-023-02449-8","article-title":"Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation","volume":"24","author":"Wang","year":"2023","journal-title":"Respir. Res."},{"key":"10.1016\/j.abb.2024.110066_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911521","article-title":"Tumor-informed approach improved ctDNA detection rate in resected pancreatic cancer","volume":"23","author":"Watanabe","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.abb.2024.110066_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169006","article-title":"Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer","volume":"23","author":"Shields","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.abb.2024.110066_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study","volume":"34","author":"Reichert","year":"2023","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.abb.2024.110066_bib29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/03008916221101927","article-title":"Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: a review","volume":"109","author":"Yan","year":"2023","journal-title":"Tumori"},{"key":"10.1016\/j.abb.2024.110066_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.abb.2024.110066_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/path.5048","article-title":"The value of cell-free DNA for molecular pathology","volume":"244","author":"Stewart","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.abb.2024.110066_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.abb.2024.110066_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12916-023-03163-4","article-title":"Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.abb.2024.110066_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/jamaoncol.2023.0425","article-title":"Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation","volume":"9","author":"Mo","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib35","first-page":"263","article-title":"Dynamic Treatment Stratification Using ctDNA. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer","volume":"215","author":"Vidal","year":"2020"},{"key":"10.1016\/j.abb.2024.110066_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.abb.2024.110066_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102362","article-title":"Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis","volume":"104","author":"Papakonstantinou","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.abb.2024.110066_bib38","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.abb.2024.110066_bib39","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","article-title":"Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.abb.2024.110066_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","article-title":"Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer","volume":"43","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.abb.2024.110066_bib41","first-page":"203","article-title":"Detection of circulating tumor cell DNA for monitoring advanced gastric cancer","volume":"13","author":"Wu","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.abb.2024.110066_bib42","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.abb.2024.110066_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-024-03209-4","article-title":"Clinical applications and perspectives of circulating tumor DNA in gastric cancer","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.abb.2024.110066_bib44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","article-title":"Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA","volume":"80","author":"Sumanasuriya","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.abb.2024.110066_bib45","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-21-3017","article-title":"Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis","volume":"28","author":"Fitzpatrick","year":"2022","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.abb.2024.110066_bib46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.abb.2024.110066_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010004","article-title":"Prognostic significance of SLFN11 methylation in plasma cell-free DNA in advanced high-grade serous ovarian cancer","volume":"14","author":"Tserpeli","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211043784","article-title":"The prognostic value of circulating tumor DNA in ovarian cancer: a meta-analysis","volume":"20","author":"Lu","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.abb.2024.110066_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41392-021-00662-9","article-title":"The molecular tumor burden index as a response evaluation criterion in breast cancer","volume":"6","author":"Yi","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.abb.2024.110066_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Medical sciences"},{"key":"10.1016\/j.abb.2024.110066_bib51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","article-title":"Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis","volume":"158","author":"Gracie","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/cancers16061197","article-title":"Harnessing ctDNA in advanced melanoma: a promising tool for informed clinical decisions","volume":"16","author":"Pikturniene","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cancers13020168","article-title":"A comprehensive analysis of baseline clinical characteristics and biomarkers associated with outcome in advanced melanoma patients treated with pembrolizumab","volume":"13","author":"Awada","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib54","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1158\/1078-0432.CCR-19-3926","article-title":"Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2051-8","article-title":"Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy","volume":"17","author":"Seremet","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.abb.2024.110066_bib56","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/cancers12061414","article-title":"Inflammatory cytokines and ctDNA are biomarkers for progression in advanced-stage melanoma patients receiving checkpoint inhibitors","volume":"12","author":"Pedersen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib57","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib58","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1002\/cncr.33118","article-title":"Association between circulating tumor DNA burden and disease burden in patients with ALK\u2010positive lung cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050940","article-title":"ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.abb.2024.110066_bib61","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.abb.2024.110066_bib62","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.abb.2024.110066_bib63","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3390\/cancers13112506","article-title":"Estrogens and progestogens in triple negative breast cancer: do they harm?","volume":"13","author":"van Barele","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib64","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.abb.2024.110066_bib65","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clbc.2022.12.006","article-title":"A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases","volume":"23","author":"Shah","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.abb.2024.110066_bib66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12916-023-03017-z","article-title":"Potential value of ctDNA monitoring in metastatic HR +\/HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial","volume":"21","author":"Chiu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.abb.2024.110066_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/1354750X.2023.2201664","article-title":"Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis","volume":"28","author":"Min","year":"2023","journal-title":"Biomarkers"},{"key":"10.1016\/j.abb.2024.110066_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75319-8","article-title":"Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening","volume":"10","author":"Sekiguchi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2024.110066_bib69","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.abb.2024.110066_bib70","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.254","article-title":"Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2\u2010targeted therapies","volume":"10","author":"Zhang","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.abb.2024.110066_bib72","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","article-title":"Colorectal cancer epidemiology: recent trends and impact on outcomes","volume":"22","author":"Baidoun","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.abb.2024.110066_bib73","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003620","article-title":"Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study","volume":"18","author":"Tie","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.abb.2024.110066_bib75","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.7150\/thno.59644","article-title":"Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.abb.2024.110066_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010021","article-title":"Circulating tumor DNA and management of colorectal cancer","volume":"16","author":"Krell","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/1010428320919198","article-title":"Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: a pilot study","volume":"42","author":"Alves","year":"2020","journal-title":"Tumor Biol."},{"key":"10.1016\/j.abb.2024.110066_bib80","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2022.09.004","article-title":"Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer","volume":"167","author":"Hou","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib81","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-20-3345","article-title":"Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer","volume":"27","author":"Paracchini","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib82","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s11547-021-01401-4","article-title":"Early stage glioblastoma: retrospective multicentric analysis of clinical and radiological features","volume":"126","author":"Ceravolo","year":"2021","journal-title":"La radiologia medica"},{"key":"10.1016\/j.abb.2024.110066_bib83","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3390\/cancers13091989","article-title":"ctDNA-based liquid biopsy of cerebrospinal fluid in brain cancer","volume":"13","author":"Escudero","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.abb.2024.110066_bib84","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1152\/japplphysiol.00108.2020","article-title":"The impact of hypoxia on blood-brain, blood-CSF, and CSF-brain barriers","volume":"131","author":"Dunn","year":"2021","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.abb.2024.110066_bib85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jjco\/hyz156","article-title":"Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas","volume":"50","author":"Zhao","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40478-022-01335-6","article-title":"Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas","volume":"10","author":"Wolter","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/j.abb.2024.110066_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdae027","article-title":"Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma","volume":"6","author":"Jones","year":"2024","journal-title":"Neuro-Oncology Advances"},{"key":"10.1016\/j.abb.2024.110066_bib88","doi-asserted-by":"crossref","first-page":"457","DOI":"10.21147\/j.issn.1000-9604.2021.04.03","article-title":"Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: a nationwide pancreas data center analysis","volume":"33","author":"Hu","year":"2021","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235623","article-title":"Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis","volume":"15","author":"Uesato","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.abb.2024.110066_bib90","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3389\/fonc.2020.01220","article-title":"Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer","volume":"10","author":"Jiang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.abb.2024.110066_bib91","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-22-3526","article-title":"Comprehensive ctDNA measurements improve prediction of clinical outcomes and enable dynamic tracking of disease progression in advanced pancreatic cancer","volume":"29","author":"Lapin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2024.110066_bib92","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer research and treatment"}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986124001875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986124001875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T13:01:39Z","timestamp":1720962099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986124001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":92,"alternative-id":["S0003986124001875"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2024.110066","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA (ctDNA) application in investigation of cancer: Bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2024.110066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110066"}}